Geneva, June 4 -- International Clinical Trials Registry received information related to the study (ACTRN12625000487415) titled 'Efficacy of Toxicity Reduction with Urethra Sparing radiation Therapy for prostate cancer (TRUST)' on May 20.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Primary Sponsor: Alfred Health
Condition:
Biopsy proven intermediate risk prostate cancer
Biopsy proven intermediate risk prostate cancer
Cancer - Prostate
Intervention:
Patients will receive stereotactic ablative radiotherapy (SABR) to the prostate, delivered in five fractions, two to the three fractions per week. This study will aim to deliver 5-fraction prostate SABR 36.25 Gy in 5 fractions to the pros...